NASDAQ:PZRX PhaseRx (PZRX) Stock Price, News & Analysis → How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad) Free PZRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.28▼$0.3450-Day Range$0.28▼$0.2852-Week Range$0.22▼$1.95Volume1.05 million shsAverage Volume1.24 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get PhaseRx alerts: Email Address Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About PhaseRxPhaseRx, Inc. operates as a biopharmaceutical company that develops a portfolio of mRNA products to correct inherited, life-threatening liver diseases in children. Its product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency; argininosuccinate lyase deficiency; and argininosuccinate synthetase deficiency. The company was founded by Robert W. Overell, Patrick S. Stayton, Allan S. Hoffman, Oliver W. Press, and Paul H. Johnson on March 9, 2006 and is headquartered in Seattle, WA.Read More Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. PZRX Stock News HeadlinesApril 14, 2024 | morningstar.comPowszechny Zaklad Ubezpieczen SA PZUJune 21, 2023 | investing.comNimbus Group AB (BOAT)April 25, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…May 15, 2023 | investing.comPhaseRx (PZRXQ) Earnings Dates & ReportsSeptember 16, 2022 | investing.comTongwei Co Ltd (600438)September 13, 2022 | investing.comDeNA Co Ltd (2432)See More Headlines Receive PZRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PhaseRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2017Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:PZRX CUSIPN/A CIK1429386 Webphaserx.com Phone(206) 805-6300FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesSteven H. Gillis Ph.D. (Age 63)Independent Chairman of the Board Robert W. Overell Ph.D. (Age 61)President, Chief Executive Officer, Principal Accounting Officer, Secretary, Director Sean Monahan Ph.D.Vice President - ChemistryMary G. Prieve Ph.D.Vice President - BiologyGordon Brandt M.D. (Age 57)Chief Medical Officer James D. WatsonHead of Corporate DevelopmentPaul H. Johnson Ph.D. (Age 73)Director Brian G. Atwood (Age 64)Independent Director Michelle Renee Griffin (Age 51)Independent Director Peggy V. Phillips (Age 63)Independent Director More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors PZRX Stock Analysis - Frequently Asked Questions How were PhaseRx's earnings last quarter? PhaseRx, Inc. (NASDAQ:PZRX) issued its quarterly earnings results on Thursday, November, 9th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.14. What other stocks do shareholders of PhaseRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseRx investors own include Avid Bioservices (CDMO), Immutep (IMMP), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Biocept (BIOC), Eleven Biotherapeutics (EBIO), Net Element (NETE), OHR Pharmaceutical (OHRP), When did PhaseRx IPO? PhaseRx (PZRX) raised $18 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 3,700,000 shares at a price of $5.00 per share. Laidlaw & Company (UK) Ltd. and Roth Capital Partners acted as the underwriters for the IPO. This page (NASDAQ:PZRX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PhaseRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
